Tari A. King, MD, FSSO, on the Past Year in Breast Cancer Research

Video

The breast cancer expert discussed the latest developments in breast cancer research and what she hopes the next year will offer this patient population.

With breast cancer being the most common cancer among women in the US outside of skin cancers, it is as important as ever for research to continue to advance treatments for this patient population.

According to the American Cancer Society, an estimated 276,480 new cases of invasive breast cancer were diagnosed in women in 2020 and an estimated 48,530 new cases of carcinoma in situ were diagnosed. Moreover, the organization estimated that approximately 42,170 women would die from breast cancer.

In an interview with CancerNetwork®, Tari A. King, MD, FSSO, associate chair for Multidisciplinary Oncology in the Department of Surgery and chief of the Division of Breast Surgery at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, as well as Anne E. Dyson Professor of Surgery in the Field of Women’s Cancers at Harvard Medical School, spoke about the latest developments in breast cancer research and what she hopes 2021 will bring for this patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

American Cancer Society. How Common Is Breast Cancer? American Cancer Society website. Published January 8, 2020. Accessed December 21, 2020. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content